featured
177Lu-Lilotomab Satetraxetan in Relapsed/Refractory Indolent Non-Hodgkin Lymphoma
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
Blood Advances
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Phase 1/2a Study of 177Lu-Lilotomab Satetraxetan in Relapsed/Refractory Indolent Non-Hodgkin Lymphoma
Blood Adv 2020 Sep 08;4(17)4091-4101, A Kolstad, T Illidge, N Bolstad, S Spetalen, U Madsbu, C Stokke, J Blakkisrud, A Løndalen, N O'Rourke, M Beasley, W Jurczak, UM Fagerli, M Kaščák, M Bayne, A Obr, J Dahle, L Rojkjaer, V Pascal, H HolteFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.